Eli Lilly and Company $LLY Shares Bought by CoreCap Advisors LLC

CoreCap Advisors LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 158.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,844 shares of the company’s stock after buying an additional 6,028 shares during the period. CoreCap Advisors LLC’s holdings in Eli Lilly and Company were worth $11,390,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of LLY. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. Jupiter Topco LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $4,667,180,000. Fifth Third Bancorp grew its holdings in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after buying an additional 1,497,423 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after buying an additional 1,208,510 shares during the last quarter. Finally, Corient Private Wealth LP purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $764,116,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside from recent levels. Benzinga report
• Positive Sentiment: Pipeline diversification remains a key bullish argument. Investors are highlighting next-generation obesity candidate retatrutide, which has shown greater weight loss in trials than Zepbound and could be filed with regulators in 2027. Lilly is also expanding its early-stage Alzheimer’s research and testing obesity drug eloralintide alongside birth control. Eli Lilly obesity business article
• Positive Sentiment: Growth extends beyond GLP-1 drugs. Jaypirca, Inluriyo and Retevmo could support oncology growth, while a new research and licensing agreement with InnoCare covers as many as five drug targets. Commentators argue that Lilly’s manufacturing expansion and broad pipeline create a growth flywheel beyond Mounjaro and Zepbound. Lilly oncology portfolio article
• Neutral Sentiment: Technical support is being watched. A move around the 50-day moving average may signal short-term stabilization, but technical indicators do not resolve the stock’s valuation or fundamental risks. LLY moving average analysis
• Negative Sentiment: Valuation and competition are weighing on sentiment. Lilly trades at a premium multiple, leaving the shares sensitive to pricing pressure, increased competition in obesity medicines and any slowdown in GLP-1 demand. New WHO childhood-obesity guidance may also create uncertainty around how these therapies are used in younger patients. WHO obesity guidance article

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. Citigroup raised their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Finally, Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 1.6%

Eli Lilly and Company stock traded down $18.95 during trading on Thursday, reaching $1,169.77. 3,090,036 shares of the company’s stock were exchanged, compared to its average volume of 2,974,879. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The firm has a market cap of $1.10 trillion, a price-to-earnings ratio of 39.25, a PEG ratio of 1.42 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company’s 50-day moving average is $1,173.51 and its two-hundred day moving average is $1,094.59.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.